Literature DB >> 34535563

Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity.

Douglas R Miller1, Mengfei Bu1, Adithya Gopinath1, Luis R Martinez1, Habibeh Khoshbouei2.   

Abstract

Methamphetamine (METH) is a potent psychostimulant that increases extracellular monoamines, such as dopamine and norepinephrine, and affects multiple tissue and cell types in the central nervous system (CNS) and peripheral immune cells. The reinforcing properties of METH underlie its significant abuse potential and dysregulation of peripheral immunity and central nervous system functions. Together, the constellation of METH's effects on cellular targets and regulatory processes has led to immune suppression and neurodegeneration in METH addicts and animal models of METH exposure. Here we extensively review many of the cell types and mechanisms of METH-induced dysregulation of the central nervous and peripheral immune systems. SIGNIFICANCE STATEMENT: Emerging research has begun to show that methamphetamine regulates dopaminergic neuronal activity. In addition, METH affects non-neuronal brain cells, such as microglia and astrocytes, and immunological cells of the periphery. Concurrent disruption of bidirectional communication between dopaminergic neurons and glia in the CNS and peripheral immune cell dysregulation gives rise to a constellation of dysfunctional neuronal, cell, and tissue types. Therefore, understanding the pathophysiology of METH requires consideration of the multiple targets at the interface between basic and clinical neuroscience.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34535563      PMCID: PMC9351721          DOI: 10.1124/jpet.121.000767

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  276 in total

Review 1.  Somatodendritic dopamine release: recent mechanistic insights.

Authors:  Margaret E Rice; Jyoti C Patel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

2.  Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein).

Authors:  J M McCord; I Fridovich
Journal:  J Biol Chem       Date:  1969-11-25       Impact factor: 5.157

Review 3.  Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Authors:  Leonard L Howell; S Stevens Negus
Journal:  Adv Pharmacol       Date:  2014

Review 4.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

Review 5.  Molecular mechanisms of calcium-dependent excitotoxicity.

Authors:  R Sattler; M Tymianski
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

6.  PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine.

Authors:  Joanna S Fowler; Carsten Kroll; Richard Ferrieri; David Alexoff; Jean Logan; Stephen L Dewey; Wynne Schiffer; David Schlyer; Pauline Carter; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Helene Benveniste; Paul Vaska; Nora D Volkow
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

7.  Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy.

Authors:  Ronald J Ellis; Meredith E Childers; Mariana Cherner; Deborah Lazzaretto; Scott Letendre; Igor Grant
Journal:  J Infect Dis       Date:  2003-12-08       Impact factor: 5.226

8.  Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases.

Authors:  Katherine Conant; Coryse St Hillaire; Caroline Anderson; David Galey; Jessica Wang; Avindra Nath
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

Review 9.  Impact of methamphetamine on infection and immunity.

Authors:  Sergio A Salamanca; Edra E Sorrentino; Joshua D Nosanchuk; Luis R Martinez
Journal:  Front Neurosci       Date:  2015-01-12       Impact factor: 4.677

10.  Small molecule induced oligomerization, clustering and clathrin-independent endocytosis of the dopamine transporter.

Authors:  Tatiana Sorkina; Shiqi Ma; Mads Breum Larsen; Simon C Watkins; Alexander Sorkin
Journal:  Elife       Date:  2018-04-09       Impact factor: 8.140

View more
  5 in total

1.  Sex-Dependent Alterations in the mRNA Expression of Enzymes Involved in Dopamine Synthesis and Breakdown After Methamphetamine Self-Administration.

Authors:  Aaron E Miller; Atul P Daiwile; Jean Lud Cadet
Journal:  Neurotox Res       Date:  2022-07-14       Impact factor: 3.978

2.  Effects and associated transcriptomic landscape changes of methamphetamine on immune cells.

Authors:  Deshenyue Kong; Jun-Hong Mao; Hong Li; Jian-Yu Wang; Yu-Yang Li; Xiao-Cong Wu; Guo-Fen Re; Hua-You Luo; Yi-Qun Kuang; Kun-Hua Wang
Journal:  BMC Med Genomics       Date:  2022-06-28       Impact factor: 3.622

Review 3.  Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts.

Authors:  Atul P Daiwile; Subramaniam Jayanthi; Jean Lud Cadet
Journal:  Neurosci Biobehav Rev       Date:  2022-04-20       Impact factor: 9.052

4.  Neuron-Microglia Contact-Dependent Mechanisms Attenuate Methamphetamine-Induced Microglia Reactivity and Enhance Neuronal Plasticity.

Authors:  Joana Bravo; Inês Ribeiro; Ana Filipa Terceiro; Elva B Andrade; Camila Cabral Portugal; Igor M Lopes; Maria M Azevedo; Mafalda Sousa; Cátia D F Lopes; Andrea C Lobo; Teresa Canedo; João Bettencourt Relvas; Teresa Summavielle
Journal:  Cells       Date:  2022-01-21       Impact factor: 6.600

5.  Dynamic immune and exosome transcriptomic responses in patients undergoing psychostimulant methamphetamine withdrawal.

Authors:  Hongjin Wu; Zunyue Zhang; Yuru Ma; Fengrong Chen; Pu Xiong; Zhenrong Xie; Guo Ding; Juehua Yu; Kunhua Wang
Journal:  Front Cell Neurosci       Date:  2022-09-27       Impact factor: 6.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.